Evolus Raises FY24 Net Revenue Guidance From $255M - $265M To $260M - $270M, Est $262.495M
Evolus Raises FY24 Net Revenue Guidance From $255M - $265M To $260M - $270M, Est $262.495M
evolus将 FY24 净营业收入指引从 25500万 - 26500万 增至 26000万 - 27000万，预计为 262.495M。
- The company continues to expect its adjusted gross profit margin for the full year 2024 to be between 68% and 71%.
- The company continues to expect to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025.
- The company projects its total net revenue can reach at least $700 million by 2028, a compound annual growth rate of 28% from 2023, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse HA dermal filler product line beginning in 2025.
- 公司继续预计其2024财年的调整毛利润率将在68%至71%之间。
- 公司继续预计在2024财年第四季度和2025财年整体上实现正的非GAAP营业收入。
- 公司预计，基于其现有的美学神经毒素业务和预计于2025年开始推出的Evolysse HA皮肤填充产品系列，其总净营业收入至少可达到2028 年$70,000万，复合年增长率为28%。
资讯热榜
更新时间